EP1242075A2 - Indole compounds - Google Patents

Indole compounds

Info

Publication number
EP1242075A2
EP1242075A2 EP00991850A EP00991850A EP1242075A2 EP 1242075 A2 EP1242075 A2 EP 1242075A2 EP 00991850 A EP00991850 A EP 00991850A EP 00991850 A EP00991850 A EP 00991850A EP 1242075 A2 EP1242075 A2 EP 1242075A2
Authority
EP
European Patent Office
Prior art keywords
compound
chloro
compounds
methylenedioxybenzyl
scheme
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00991850A
Other languages
German (de)
French (fr)
Other versions
EP1242075A4 (en
Inventor
Robert A. Daines
George Wai-Kin Chan
Kelvin Kin Cheong Sham
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP1242075A2 publication Critical patent/EP1242075A2/en
Publication of EP1242075A4 publication Critical patent/EP1242075A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/14—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems

Definitions

  • This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.
  • the pathway for the biosynthesis of saturated fatty acids is very similar in prokaryotes and eukaryotes.
  • Vertebrates and yeasts possess type I fatty acid synthases (FASs) in which all of the enzymatic activities are encoded on one or two polypeptide chains, respectively.
  • FOSs type I fatty acid synthases
  • ACP acyl carrier protein
  • each of the reactions are catalyzed by distinct monofunctional enzymes and the ACP is a discrete protein.
  • Mycobacteria are unique in that they possess both type I and II FASs; the former is involved in basic fatty acid biosynthesis whereas the latter is involved in synthesis of complex cell envelope lipids such as mycolic acids. There therefore appears to be considerable potential for selective inhibition of the bacterial systems by broad-spectrum antibacterial agents (Jackowski, S. 1992. In Emerging Targets in Antibacterial and Antifungal Chemotherapy. Ed. J. Sutcliffe & N. Georgopapadakou. Chapman & Hall, New York; Jackowski, S. et al. (1989). J. Biol. Chem. 264, 7624-7629.)
  • the first step in the biosynthetic cycle is the condensation of malonyl-ACP with acetyl-CoA by FabH.
  • malonyl-ACP is condensed with the growing- chain acyl-ACP (FabB and FabF, synthases I and II respectively).
  • the second step in the elongation cycle is ketoester reduction by NADPH-dependent ⁇ -ketoacyl-ACP reductase (FabG).
  • Fab H is therefore a major biosynthetic enzyme which is also a key regulatory point in the overall synthetic pathway (Heath, R.J. and Rock, CO. 1996. J.Biol.Chem. 271, 1833-1836; Heath, R.J. and Rock, CO. 1996. J.Biol.Chem. 271, 10996-
  • the antibiotic thiolactomycin has broad- spectrum antibacterial activity both in vivo and in vitro and has been shown to specifically inhibit all three condensing enzymes. It is non-toxic and does not inhibit mammalian FASs (Hayashi, T. et al.,1984. J. Antibiotics 37, 1456-1461; Miyakawa, S. et al., 1982. J. Antibiotics 35, 411-419; Nawata, Y et al., 1989. Acta Cryst. C45, 978-979; Noto, T. et al., 1982. J. Antibiotics 35, 401-410; Oishi, H. et al., 1982. J. Antibiotics 35, 391-396.
  • cerulenin is a potent inhibitor of FabB & F and is bactericidal but is toxic to eukaryotes because it competes for the fatty-acyl binding site common to both FAS types (DAgnolo, G. et al.,1973. Biochim. Biophys. Acta. 326,
  • This invention comprises indole derivatives and pharmaceutical compositions containing these compounds, and their use as FabH inhibitors, which are useful as antibiotics for the treatment of Gram positive, and Gram negative bacterial infections.
  • This invention further constitutes a method for treatment of a Gram negative or Gram positive bacterial infection in an animal, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of this invention.
  • R is OH
  • Q is O, NH or CH 2 or a pharmaceutically acceptable salt thereof.
  • compositions of this invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are contemplated to be within the scope of the present invention.
  • solvates may be formed.
  • This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.
  • the antibiotic compounds of the invention are intended for use in pharmaceutical compositions it will readily be understood that they are each provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 95% pure, particularly at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1 %, more suitably at least 5% and preferably from 10 to 49% of a compound of the formula (I) or salt thereof.
  • Preferred compounds have Q as O or NH.
  • Preferred compounds are l-(6-chloro-3,4-methylenedioxybenzyl)-5-(2,6- dichlorobenzyloxy)indole-2-carboxylic acid and l-(6-chloro-3,4-methylenedioxybenzyl)-5- (2,6-dichlorobenzylamino)indole-2-carboxylic acid.
  • 2-Scheme-l is dissolved in a solvent (such as ethyl acetate) and treated with 10% Palladiun on charcoal and the resulting mixture shaken (6 hours to 30 hours, preferably 20 hours) to yield 3-Scheme- 1.
  • a solvent such as ethyl acetate
  • 2-Scheme-l is dissolved in a solvent (such as ethyl acetate) and treated with 10% Palladiun on charcoal and the resulting mixture shaken (6 hours to 30 hours, preferably 20 hours) to yield 3-Scheme- 1.
  • Alkylation of 3-Scheme-l with 2,6-dichlorobenzyl bromide using a base (such as sodium hydride) in a solvent (such as DMF) provides 4-Scheme- 1.
  • Saponification of 4-Scheme- 1 with a base (such as potassium hydroxide) in a solvent such as ethanol and tetrahydrofuran) provides 5-Scheme-l.
  • the commercially available 5-nitroindole 6-Scheme-2 was alkylated with 6- chloropiperonyl chloride using a base such as NaH in a polar aprotic solvent such as DMF.
  • Scheme-2 was achieved via use of NaH as base and 2,6-dichlorobenzyl chloride as alkylating agent.
  • the synthesis of 10-Scheme-2 was completed by standard hydrolysis of the ethyl ester of 9-Scheme-2.
  • the assay is designed to measure IC50s against Streptococcus pneumoniae ⁇ -ketoacyl-ACP synthase III (FabH). Substrates malonyl-ACP, [14C]-acetyl-coA are combined with FabH to produce [14C]-acetoacetyl-ACP.
  • FabH Streptococcus pneumoniae ⁇ -ketoacyl-ACP synthase III
  • Total reaction volume is 50ul.
  • a panel of 12 strains were evaluated in the assay. This panel consisted of the following laboratory strains: Staphylococcus aureus Oxford, Streptococcus pneumoniae R6, Streptococcus pyogenes CN10, Enterococcus faecalis I, Haemophilus influenzae Ql, Escherichia coli DCO, E. coli ESS, E. coli 7623 (Acr A + ) E. coli 120 (AcrAB " ) Klebsiella pneumoniae E70, Pseudomonas aeruginosa K799wt and Candida albicans GRI 681. The minimum inhibitory concentration (MIC) was determined as the lowest concentration of compound that inhibited visible growth.
  • the present invention also provides a pharmaceutical composition that comprises a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof and a pharmaceutically acceptable carrier.
  • the compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans.
  • the antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics.
  • compositions may be formulated for administration by any route, such as oral, topical or parenteral, especially oral.
  • the compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
  • topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.
  • the formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions.
  • suitable conventional carriers such as cream or ointment bases and ethanol or oleyl alcohol for lotions.
  • Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.
  • Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate.
  • the tablets may be coated according to methods well known in normal pharmaceutical practice.
  • Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
  • Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavoring or coloring agents.
  • suspending agents for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or
  • Suppositories will contain conventional suppository bases, e.g. cocoa butter or other glyceride.
  • fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred.
  • the compound depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle.
  • the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing.
  • the solution preferably contains a buffer (such as phosphate) to keep the pH in the range of about 3.5 to 7.
  • DMSO or alcoholic solvents may also be present (at concentrations such as 0.01 to 10 mL/liter) to aid solubility and penetration of the compound of Formula (I)
  • agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle.
  • the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use.
  • Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration.
  • the compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
  • a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
  • compositions may contain from 0.1 % by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient.
  • the dosage as employed for adult human treatment will preferably range from 1 to 140 mg/kg of body weight, depending on the route and frequency of administration.. No unacceptable toxicological effects are expected when a compound of formula
  • the compound of formula (I) may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or compounds which enhance the antibacterial activity of a compound of formula (I)may be employed.
  • the antibiotic compounds of the present invention are active against a wide range of organisms including both Gram-negative organisms such as Escherichia coli and Klebsiella pneumoniae and Gram-positive organisms such as Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis and Enterococcus faecium, including isolates resistant to existing antibiotics.
  • Example 1 Preparation of 1 -(6-chloro-3,4-methy lenedioxybenzyl)-5-(2,6-dichlorobenzyloxy)indole-2- carboxylic acid a) Ethyl- l-(6-chloro-3,4-methylenedioxybenzyl)-5-(benzyloxy)indolecarboxylate. To a solution of NaH (6.1g, 0.15 mol; 60% dispersion in hexane) rinsed with hexane in DMF (500 mL) was added 5-benzyloxy-2-indolecarboxylic acid ethyl ester (30g, 0.1 mol) .

Abstract

This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.

Description

INDOLE COMPOUNDS
FIELD OF THE INVENTION
This invention relates to the use of compounds as inhibitors of the fatty acid synthase FabH.
BACKGROUND OF THE INVENTION
The pathway for the biosynthesis of saturated fatty acids is very similar in prokaryotes and eukaryotes. However, although the chemical reactions may not vary, the organization of the biosynthetic apparatus is very different. Vertebrates and yeasts possess type I fatty acid synthases (FASs) in which all of the enzymatic activities are encoded on one or two polypeptide chains, respectively. The acyl carrier protein (ACP) is an integral part of the complex. In contrast, in most bacterial and plant FASs (type II) each of the reactions are catalyzed by distinct monofunctional enzymes and the ACP is a discrete protein. Mycobacteria are unique in that they possess both type I and II FASs; the former is involved in basic fatty acid biosynthesis whereas the latter is involved in synthesis of complex cell envelope lipids such as mycolic acids. There therefore appears to be considerable potential for selective inhibition of the bacterial systems by broad-spectrum antibacterial agents (Jackowski, S. 1992. In Emerging Targets in Antibacterial and Antifungal Chemotherapy. Ed. J. Sutcliffe & N. Georgopapadakou. Chapman & Hall, New York; Jackowski, S. et al. (1989). J. Biol. Chem. 264, 7624-7629.)
The first step in the biosynthetic cycle is the condensation of malonyl-ACP with acetyl-CoA by FabH. In subsequent rounds malonyl-ACP is condensed with the growing- chain acyl-ACP (FabB and FabF, synthases I and II respectively). The second step in the elongation cycle is ketoester reduction by NADPH-dependent β-ketoacyl-ACP reductase (FabG). Subsequent dehydration by β-hydroxyacyl-ACP dehydrase (either FabA or FabZ) leads to trans-2-enoyl-ACP which is in turn converted to acyl-ACP by NADH-dependent enoyl-ACP reductase (Fabl). Further rounds of this cycle, adding two carbon atoms per cycle, eventually lead to palmitoyl-ACP whereupon the cycle is stopped largely due to feedback inhibition of FabH and I by palmitoyl-ACP (Heath, et al, (1996), J.Biol.Chem. 271, 1833-1836). Fab H is therefore a major biosynthetic enzyme which is also a key regulatory point in the overall synthetic pathway (Heath, R.J. and Rock, CO. 1996. J.Biol.Chem. 271, 1833-1836; Heath, R.J. and Rock, CO. 1996. J.Biol.Chem. 271, 10996-
11000).
The antibiotic thiolactomycin has broad- spectrum antibacterial activity both in vivo and in vitro and has been shown to specifically inhibit all three condensing enzymes. It is non-toxic and does not inhibit mammalian FASs (Hayashi, T. et al.,1984. J. Antibiotics 37, 1456-1461; Miyakawa, S. et al., 1982. J. Antibiotics 35, 411-419; Nawata, Y et al., 1989. Acta Cryst. C45, 978-979; Noto, T. et al., 1982. J. Antibiotics 35, 401-410; Oishi, H. et al., 1982. J. Antibiotics 35, 391-396. Similarly, cerulenin is a potent inhibitor of FabB & F and is bactericidal but is toxic to eukaryotes because it competes for the fatty-acyl binding site common to both FAS types (DAgnolo, G. et al.,1973. Biochim. Biophys. Acta. 326,
155-166). Extensive work with these inhibitors has proved that these enzymes are essential for viability. Little work has been carried out in Gram-positive bacteria.
There is an unmet need for developing new classes of antibiotic compounds that are not subject to existing resistance mechanisms. No marketed antibiotics are targeted against fatty acid biosynthesis, therefore it is unlikely that novel antibiotics of this type would be rendered inactive by known antibiotic resistance mechanisms. Moreover, this is a potentially broad-spectrum target. Therefore, FabH inhibitors would serve to meet this unmet need.
SUMMARY OF THE INVENTION
This invention comprises indole derivatives and pharmaceutical compositions containing these compounds, and their use as FabH inhibitors, which are useful as antibiotics for the treatment of Gram positive, and Gram negative bacterial infections.
This invention further constitutes a method for treatment of a Gram negative or Gram positive bacterial infection in an animal, including humans, which comprises administering to an animal in need thereof, an effective amount of a compound of this invention.
DETAILED DESCRIPTION OF THE INVENTION
The compounds of this invention are represented by Formula (I):
( I ) wherein:
R is OH; and
Q is O, NH or CH2 or a pharmaceutically acceptable salt thereof.
Also included in the invention are pharmaceutically acceptable salt complexes. The compounds of this invention may contain one or more asymmetric carbon atoms and may exist in racemic and optically active forms. All of these compounds and diastereomers are contemplated to be within the scope of the present invention.
Some of the compounds of this invention may be crystallised or recrystallised from solvents such as organic solvents. In such cases solvates may be formed. This invention includes within its scope stoichiometric solvates including hydrates as well as compounds containing variable amounts of water that may be produced by processes such as lyophilisation.
Since the antibiotic compounds of the invention are intended for use in pharmaceutical compositions it will readily be understood that they are each provided in substantially pure form, for example at least 60% pure, more suitably at least 75% pure and preferably at least 85%, especially at least 95% pure, particularly at least 98% pure (% are on a weight for weight basis). Impure preparations of the compounds may be used for preparing the more pure forms used in the pharmaceutical compositions; these less pure preparations of the compounds should contain at least 1 %, more suitably at least 5% and preferably from 10 to 49% of a compound of the formula (I) or salt thereof.
Preferred compounds have Q as O or NH.
Preferred compounds are l-(6-chloro-3,4-methylenedioxybenzyl)-5-(2,6- dichlorobenzyloxy)indole-2-carboxylic acid and l-(6-chloro-3,4-methylenedioxybenzyl)-5- (2,6-dichlorobenzylamino)indole-2-carboxylic acid.
Compounds of the formula I wherein Q is O are prepared by the method described in Scheme 1.
Scheme 1
a) 6-chloropiperonyl chloride, NaH, DMF; b) 10% Pd/C, H2, EtOAc; c) 2,6 dichlorobenzyl bromide, NaH, DMF; d) KOH, EtOH/THF, reflux Indole ester 1 -Scheme- 1 (Aldrich) and a base (such as sodium hydride) are treated with a solvent (such as DMF) and then 6-chloropiperonyl chloride is added and stirred (6 hours to 30 hours, preferably 20 hours) to yield 2-Scheme-l . 2-Scheme-l is dissolved in a solvent (such as ethyl acetate) and treated with 10% Palladiun on charcoal and the resulting mixture shaken (6 hours to 30 hours, preferably 20 hours) to yield 3-Scheme- 1. Alkylation of 3-Scheme-l with 2,6-dichlorobenzyl bromide using a base (such as sodium hydride) in a solvent (such as DMF) provides 4-Scheme- 1. Saponification of 4-Scheme- 1 with a base (such as potassium hydroxide) in a solvent (such as ethanol and tetrahydrofuran) provides 5-Scheme-l.
Compounds of the formula I wherein Q is NH are prepared by the method described in Scheme 2. Scheme 2
a) 6-chloropiperonyl chloride, NaH, DMF; b) SnCl2, EtOH, 70 °C; c) 2,6-dichlorobenzyl chloride, NaH, DMF; d) 1) NaOH, THF, MeOH. 2) 10% HC1.
The commercially available 5-nitroindole 6-Scheme-2 was alkylated with 6- chloropiperonyl chloride using a base such as NaH in a polar aprotic solvent such as DMF.
This alkylation procedure provided nitroindole 7-Scheme-2. Reduction of the nitro group to the corresponding amine 8-Scheme-2 was accomplished using tin(II) chloride as the reducing agent, although other suitable reagents could be used. N-alkylation to give 9-
Scheme-2 was achieved via use of NaH as base and 2,6-dichlorobenzyl chloride as alkylating agent. The synthesis of 10-Scheme-2 was completed by standard hydrolysis of the ethyl ester of 9-Scheme-2.
Biological Assay:
FabH inhibition
The assay is designed to measure IC50s against Streptococcus pneumoniae β-ketoacyl-ACP synthase III (FabH). Substrates malonyl-ACP, [14C]-acetyl-coA are combined with FabH to produce [14C]-acetoacetyl-ACP.
Conditions of assay; sodium phosphate pH 7.0 lOOmM beta-mercaptoethanol lmM malonyl acyl carrier protein 20uM acetyl coenzymeA 70uM
[1-14C] acetyl coenzyme-A 5uM FabH 1-16nM
Total reaction volume is 50ul.
1 ) Compile all reagents minus enzyme and aliquot onto a 96 well plate already containing inhibitors.
2) Dilute FabH into assay buffer with ImM beta-mercaptoethanol and add to the plate to start the reaction, and incubate at 37C for 40 minutes. 3) Stop reactions with 150ul 10%TCA.
4) Pre- wet GF/C filter mat with 10%TCA, filter stopped reactions, rinse wells with 150 ul of 10%TCA twice and filter.
5) Oven dry filter mat at 60C, seal filter mat in a clear plastic bag, add Betaplate scintillation cocktail and count with Wallac Microbeta liquid scintillation counter.
Antimicrobial Activity Assay:
Whole-cell antimicrobial activity was determined by broth microdilution using the National Committee for Clinical Laboratory Standards (NCCLS) recommended procedure, Document M7-A4, "Methods for Dilution Susceptibility Tests for Bacteria that Grow Aerobically" (incorporated by reference herein). The compound was tested in serial twofold dilutions ranging from 0.06 to 64 mcg/ml.
A panel of 12 strains were evaluated in the assay. This panel consisted of the following laboratory strains: Staphylococcus aureus Oxford, Streptococcus pneumoniae R6, Streptococcus pyogenes CN10, Enterococcus faecalis I, Haemophilus influenzae Ql, Escherichia coli DCO, E. coli ESS, E. coli 7623 (Acr A +) E. coli 120 (AcrAB") Klebsiella pneumoniae E70, Pseudomonas aeruginosa K799wt and Candida albicans GRI 681. The minimum inhibitory concentration (MIC) was determined as the lowest concentration of compound that inhibited visible growth. A mirror reader was used to assist in determining the MIC endpoint. The present invention also provides a pharmaceutical composition that comprises a compound of formula (I) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof and a pharmaceutically acceptable carrier. The compositions of the invention include those in a form adapted for oral, topical or parenteral use and may be used for the treatment of bacterial infection in mammals including humans. The antibiotic compounds according to the invention may be formulated for administration in any convenient way for use in human or veterinary medicine, by analogy with other antibiotics.
The composition may be formulated for administration by any route, such as oral, topical or parenteral, especially oral. The compositions may be in the form of tablets, capsules, powders, granules, lozenges, creams or liquid preparations, such as oral or sterile parenteral solutions or suspensions.
The topical formulations of the present invention may be presented as, for instance, ointments, creams or lotions, eye ointments and eye or ear drops, impregnated dressings and aerosols, and may contain appropriate conventional additives such as preservatives, solvents to assist drug penetration and emollients in ointments and creams.
The formulations may also contain compatible conventional carriers, such as cream or ointment bases and ethanol or oleyl alcohol for lotions. Such carriers may be present as from about 1% up to about 98% of the formulation. More usually they will form up to about 80% of the formulation.
Tablets and capsules for oral administration may be in unit dose presentation form, and may contain conventional excipients such as binding agents, for example syrup, acacia, gelatin, sorbitol, tragacanth, or polyvinylpyrollidone; fillers, for example lactose, sugar, maize-starch, calcium phosphate, sorbitol or glycine; tabletting lubricants, for example magnesium stearate, talc, polyethylene glycol or silica; disintegrants, for example potato starch; or acceptable wetting agents such as sodium lauryl sulphate. The tablets may be coated according to methods well known in normal pharmaceutical practice. Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives, such as suspending agents, for example sorbitol, methyl cellulose, glucose syrup, gelatin, hydroxyethyl cellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example almond oil, oily esters such as glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl p-hydroxybenzoate or sorbic acid, and, if desired, conventional flavoring or coloring agents.
Suppositories will contain conventional suppository bases, e.g. cocoa butter or other glyceride. For parenteral administration, fluid unit dosage forms are prepared utilizing the compound and a sterile vehicle, water being preferred. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions the compound can be dissolved in water for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. The solution preferably contains a buffer (such as phosphate) to keep the pH in the range of about 3.5 to 7. DMSO or alcoholic solvents may also be present (at concentrations such as 0.01 to 10 mL/liter) to aid solubility and penetration of the compound of Formula (I) Advantageously, agents such as a local anaesthetic, preservative and buffering agents can be dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. The dry lyophilized powder is then sealed in the vial and an accompanying vial of water for injection may be supplied to reconstitute the liquid prior to use. Parenteral suspensions are prepared in substantially the same manner except that the compound is suspended in the vehicle instead of being dissolved and sterilization cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspending in the sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.
The compositions may contain from 0.1 % by weight, preferably from 10-60% by weight, of the active material, depending on the method of administration. Where the compositions comprise dosage units, each unit will preferably contain from 50-500 mg of the active ingredient. The dosage as employed for adult human treatment will preferably range from 1 to 140 mg/kg of body weight, depending on the route and frequency of administration.. No unacceptable toxicological effects are expected when a compound of formula
(la) or a pharmaceutically acceptable salt or in vivo hydrolysable ester thereof is administered in the above-mentioned dosage range.
The compound of formula (I) may be the sole therapeutic agent in the compositions of the invention or a combination with other antibiotics or compounds which enhance the antibacterial activity of a compound of formula (I)may be employed.
The antibiotic compounds of the present invention are active against a wide range of organisms including both Gram-negative organisms such as Escherichia coli and Klebsiella pneumoniae and Gram-positive organisms such as Staphylococcus aureus, Streptococcus pneumoniae, Enterococcus faecalis and Enterococcus faecium, including isolates resistant to existing antibiotics.
The following Examples illustrate the preparation of compounds of the invention and intermediates thereto.
Example 1 Preparation of 1 -(6-chloro-3,4-methy lenedioxybenzyl)-5-(2,6-dichlorobenzyloxy)indole-2- carboxylic acid a) Ethyl- l-(6-chloro-3,4-methylenedioxybenzyl)-5-(benzyloxy)indolecarboxylate. To a solution of NaH (6.1g, 0.15 mol; 60% dispersion in hexane) rinsed with hexane in DMF (500 mL) was added 5-benzyloxy-2-indolecarboxylic acid ethyl ester (30g, 0.1 mol) . The resulting mixture was stirred at room temperature for lh. Chloropiperonyl chloride (20.85g,0.1 mol) was added. The resulting mixture was stirred at room temperature for 24h. The resulting mixture was poured into water and extracted EtOAc (2X). The combined organic layer was washed with H20, brine, dried (MgSθ4), filtered, and concentrated in vacuum to give a solid. The solid was recrystilized from ethanol to yield title compound as a white solid (30.68g, 66%). MS (ES+) m/e 464.5[M+H]+.
b) Ethyl- 1 -(6-chloro-3,4-methylenedioxybenzyl)-5-(hydroxy)indolecarboxylate. To a solution of Ethyl- 1 -(6-chloro-3,4-methylenedioxybenzyl)-5-
(benzyloxy)indolecarboxylate (22.67g, 0.046 mol) in EtOAc (800 mL) was adde4d 10% Pd on carbon (11.34g, 50% w/w). The resulting mixture was hydrogenated in Parr shaker at 60 psi for 18h. The resulting mixture was filtered through Celite, concentrated in vacuum to yield title compound as a white solid (14.54g, 80%). MS (ES+) m/e 374.4[M+H]+.
c) Ethyl- 1 -(6-chloro-3,4-methylenedioxybenzyl)-5-(2,6-dichlorobenzyloxy) indolecarboxylate.
To a solution of NaH (2.34g, 0.06 mol; 60% dispersion in hexane) rinsed with hexane in DMF (390 mL) was added Ethyl- l-(6-chloro-3,4-methylenedioxybenzyl)-5- (hydroxy)indolecarboxylate (14.54g, 0.04 mol) . The resulting mixture was stirred at room temperature for lh. 2,6-Dichlorobenzyl bromide (9.36g,0.045 mol) was added. The resulting mixture was stirred at room temperature for lh. The resulting mixture was poured into water and extracted EtOAc (2X). The combined organic layer was washed with H20, brine, dried (MgSθ4), filtered, and concentrated in vacuum to give a solid. The solid was recrystilized from EtOAc to yield title compound as a white solid (17.07g, 82%). MS (ES+) m/e 515.2[M+H]+.
d) l-(6-chloro-3,4-methylenedioxybenzyl)-5-(2,6-dichlorobenzyloxy)indole-2-carboxylic acid.
To a solution of Ethyl- l-(6-chloro-3,4-methylenedioxybenzyl)-5-(2,6- dichlorobenzyloxy)indolecarboxylate (5g, 9.7 mmol) in THF (210 mL) and EtOH (210 mL) was adde KOH (210 mL, 3N solution in H20). The resulting mixture was refluxed for 2h. The resulting mixture was partitioned between EtOAc and 3N HC1. The combined organic layer was washed with H20, brine, dried (MgSθ4), filtered, and concentrated in vacuum to give a solid. The solid was recrystilized from EtOAc to yield title compound as a white solid (4.7g, 97%). MS (ES+) m/e 505.2[M+H]+.
Example 2 Preparation of 1 -(6-chloro-3,4-methylenedioxybenzyl)-5-(2,6-dichlorobenzylamino)indole- 2-carboxylic acid a) Ethyl 1 -(6-chloro-3,4-methylenedioxybenzyl)-5-nitroindole-2-carboxylate
A solution of ethyl 5-nitroindole-2-carboxylate (0.5 g, 2.1 mmol) in anhydrous DMF (4 mL) was treated with NaH (60% dispersion in mineral oil) (93 mg, 2.3 mmol) and stirred for 5 minutes, during which 6-chloro-3,4-methylenedioxybenzyl chloride (0.47g, 2.3 mmol) was added. The resulting mixture was stirred at room temperature for 20 h. The reaction mixture was diluted with EtOAc and washed with water and brine. The organic extract was dried over Na2Sθ4, filtered, and concentrated in vacuo; the resulting residue was chromatographed over silica with 5%, 10%, 15%, and 20% EtOAc/hexane to afford the title compound (1.32 g, 82%) as an off-white solid. ES (MS) m/e 403.2 [M+H]+.
b) Ethyl 1 -(6-chloro-3,4-methylenedioxybenzyl)-5-aminoindole-2-carboxylate
A solution of the compound of Example 2a (0.31 g, 0.77 mmol) in ethanol (5 mL)
0 was treated with tin(II) chloride (0.73 g, 4 mmol) and heated at 70 C for 6 h. The reaction was poured into ice, made basic with aqueous 50% NaOH, and washed exhaustively with EtOAc. The combined organic extract was dried over Na Sθ4, filtered, and concentrated in vacuo; the resulting residue was chromatographed over silica with 25%, 30%, 35%, and 40% EtOAc/hexane to afford the title compound (172 mg, 60%) as a brick-colored solid. ES (MS) m/e 372.9 [M+H]+. c) Ethyl 1 -(6-chloro-3,4-methylenedioxybenzyl)-5-(2,6-dichlorobenzylamino)indole-2- carboxylate
Following the procedure of Example 2a, except for substituting ethyl 5-nitroindole- 2-carboxylate with the compound of Example 2b and 6-chloro-3,4-methylenedioxybenzyl chloride with 2,6-dichlorobenzyl chloride, the title compound was prepared as light yellow glassy foam. ES (MS) m/e 530.78 [M]+.
d) l-(6-Chloro-3,4-methylenedioxybenzyl)-5-(2,6-dichlorobenzylamino)indole-2- carboxylic acid
A solution of the compound of Example 2c (46 mg, 0.086 mmol) in anhydrous THF (0.4 mL) and methanol (0.2 mL) was treated with aquoeus IN NaOH (0.22 mL, 0.22 mmol) and stirred for 20 h. After removing the solvent mixture in vacuo, the resulting sodium salt was suspended in water and acidified with 10% HCl (to pH = 6.5) to afford the title compound (35 mg, 80%) as a dirty yellow solid. ES (MS) m/e 504.65 [M+2H]+.

Claims

What is claimed is
1 A method of treating bacterial infections by administering to a patient in need thereof an effective amount of a compound of Formula (I)
wherein
R is OH, and
Q is O, NH or CH2, or a pharmaceutically acceptable salt thereof
2 A method of treatment according to Claim 1 wherein the compound of Formula (I) is l-(6-chloro-3,4-methylenedιoxybenzyl)-5-(2,6-dιchlorobenzyloxy)ιndole-2-carboxylιc acid
3 A method of treatment according to Claim 1 wherein the compound of Formula (I) is 1 -(6-chloro-3 ,4-methylenedιoxybenzyl)-5-(2,6-dιchlorobenzylamιno)ιndole-2-carboxyhc
EP00991850A 1999-10-22 2000-10-20 Indole compounds Withdrawn EP1242075A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16112299P 1999-10-22 1999-10-22
US161122P 1999-10-22
PCT/US2000/029082 WO2001030752A2 (en) 1999-10-22 2000-10-20 Indole compounds for treating bacterial infections

Publications (2)

Publication Number Publication Date
EP1242075A2 true EP1242075A2 (en) 2002-09-25
EP1242075A4 EP1242075A4 (en) 2002-12-04

Family

ID=22579913

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00991850A Withdrawn EP1242075A4 (en) 1999-10-22 2000-10-20 Indole compounds

Country Status (4)

Country Link
EP (1) EP1242075A4 (en)
JP (1) JP2003512452A (en)
AU (1) AU3634001A (en)
WO (1) WO2001030752A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2905751A1 (en) 2013-03-13 2014-10-09 Forma Therapeutics, Inc. Novel compounds and compositions for inhibition of fasn
EP3873214A4 (en) 2018-10-29 2022-07-13 Forma Therapeutics, Inc. Solid forms of (4-(2-fluoro-4-(1-methyl-1 h-benzo[d]imidazol-5-yl)benzoyl) piperazin-1-yl)(1-hydroxycyclopropyl)methanone

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018393A1 (en) * 1994-12-13 1996-06-20 Smithkline Beecham Corporation Novel compounds
WO1997035572A1 (en) * 1996-03-28 1997-10-02 Smithkline Beecham Corporation Carboxylic acid indole inhibitors of chemokines
WO2001030775A1 (en) * 1999-10-22 2001-05-03 Smithkline Beecham Corporation Novel indole compounds
WO2002000620A1 (en) * 2000-06-27 2002-01-03 Smithkline Beecham Corporation Fatty acid synthase inhibitors

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996018393A1 (en) * 1994-12-13 1996-06-20 Smithkline Beecham Corporation Novel compounds
WO1997035572A1 (en) * 1996-03-28 1997-10-02 Smithkline Beecham Corporation Carboxylic acid indole inhibitors of chemokines
WO2001030775A1 (en) * 1999-10-22 2001-05-03 Smithkline Beecham Corporation Novel indole compounds
WO2002000620A1 (en) * 2000-06-27 2002-01-03 Smithkline Beecham Corporation Fatty acid synthase inhibitors

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO0130752A2 *

Also Published As

Publication number Publication date
JP2003512452A (en) 2003-04-02
EP1242075A4 (en) 2002-12-04
WO2001030752A2 (en) 2001-05-03
WO2001030752A3 (en) 2001-11-22
AU3634001A (en) 2001-05-08

Similar Documents

Publication Publication Date Title
US6469046B1 (en) Indole compounds useful for treating bacterial infections
KR20090034395A (en) Inhibitors of undecaprenyl pyrophosphate synthase
US6608059B1 (en) Fatty acid synthase inhibitors
CA2824403A1 (en) Solid forms of gyrase inhibitor (r)-1-ethyl-3-[6-fluoro-5-[2-(1-hydroxy-1-methyl-ethyl)pyrimidin-5-yl]-7-(tetrahydrofuran-2-yl)-1h-benzimidazol-2-yl]urea
US6486211B1 (en) Indole compounds
US6723749B2 (en) Fatty acid synthase inhibitors
US6559179B1 (en) Fatty acid synthase inhibitors
US6670388B1 (en) Fatty acid synthase inhibitors
EP1242075A2 (en) Indole compounds
US6498187B1 (en) Fatty acid synthase inhibitors
US6486192B1 (en) Indole compounds useful for treating bacterial infections
WO2002055661A2 (en) Fatty acid synthase inhibitors
WO2000077003A1 (en) Optically active pyrrolopyridazine compounds
EP0635269A1 (en) Use of N-(Pyridinyl)-1H-Indol-1-Amines for the preparation of a medicament for the treatment of obsessive-compulsive disorders
CA1258264A (en) .beta.-METHYLENETHIOPHENETHANAMINES
WO2002002119A1 (en) Fatty acid synthase inhibitors
WO2001014362A1 (en) Fatty acid synthase inhibitors
EP1318806A1 (en) Fatty acid synthase inhibitors
US4923868A (en) 8-fluoro and 7,8,10-trifluoro-9-(substituted)-6-oxo-6H-benzo(C)quinolizine-5-carboxylic acids
HUT67679A (en) Novel fluorinated quinolones, process for their preparation and pharmaceutical preparations containing same
JPH07233059A (en) Antimicrobial agent
JPH0770083A (en) Antihypertensive agent containing imidazole derivative as active ingredient
NZ612961A (en) Pyrimidine gyrase and topoisomerase iv inhibitors
JP2004137198A (en) Antibacterial agent having pyrazole skeleton
NZ612961B2 (en) Pyrimidine gyrase and topoisomerase iv inhibitors

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20020514

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20021018

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

RIC1 Information provided on ipc code assigned before grant

Free format text: 7A 61K 31/404 A, 7A 61P 31/04 B, 7C 07D 405/06 B

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20040501